Login / Signup

Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial.

Laura Deborah LocatiStefano CavalieriCristiana BergaminiCarlo ResteghiniElena ColomboGiuseppina CalaresoLuigi MarianiPasquale QuattroneSalvatore AlfieriPaolo BossiFrancesca PlatiniIolanda CaponeLisa F Licitra
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Abiraterone plus luteinizing hormone-releasing hormone agonist is active and safe as a second-line option in AR-expressing, castration-resistant SGC.
Keyphrases
  • papillary thyroid
  • squamous cell
  • open label
  • clinical trial
  • squamous cell carcinoma
  • wild type
  • placebo controlled